Stockscreener 앱 받기
1.54
6.10%
-0.10
시간 외 거래:
1.53
-0.01
-0.65%
전일 마감가:
$1.64
열려 있는:
$1.62
하루 거래량:
795.66K
Relative Volume:
0.23
시가총액:
$132.26M
수익:
$32.31M
순이익/손실:
$-237.09M
주가수익비율:
-0.5347
EPS:
-2.88
순현금흐름:
$-219.11M
1주 성능:
-2.53%
1개월 성능:
+49.51%
6개월 성능:
-50.64%
1년 성능:
-72.84%
1일 변동 폭
$1.53
$1.6488
1주일 범위
$1.45
$1.73
52주 변동 폭
$0.9101
$6.69
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
EDIT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.54 | 132.26M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | H.C. Wainwright | Buy |
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May - GlobeNewswire
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor ... - Eagle-Tribune
Editas Medicine Earnings Alert: Q1 2025 Results Coming May 12, Ends Quarterly Calls - Stock Titan
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by HC Wainwright - MarketBeat
Editas Medicine (NASDAQ:EDIT) Upgraded at Cantor Fitzgerald - MarketBeat
Zacks Research Raises Earnings Estimates for Editas Medicine - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $6.83 Consensus Target Price from Analysts - MarketBeat
HC Wainwright Comments on Editas Medicine Q1 Earnings - MarketBeat
Editas Medicine Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Purchases New Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
HC Wainwright & Co. Initiates Coverage of Editas Medicine (LSE:0IFK) with Buy Recommendation - Nasdaq
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Barchart.com
Editas Medicine (EDIT) Receives Positive Coverage from H.C. Wain - GuruFocus
HC Wainwright & Co. Initiates Coverage of Editas Medicine (EDIT) with Buy Recommendation - Nasdaq
Editas Medicine to Present Preclinical Data Demonstrating Progre - GuruFocus
Editas Medicine to Present Five Abstracts at the 28th Annual Meeting of the American Society of Gene and Cell Therapy - Nasdaq
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in ... - Bluefield Daily Telegraph
Editas Unveils Game-Changing In Vivo Gene Editing Breakthroughs: 5 Major Studies at ASGCT 2025 - Stock Titan
Recent uptick might appease Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners after losing 71% over the past year - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Leerink Partnrs Forecasts Editas Medicine Q3 Earnings - MarketBeat
Cell and Gene Therapy Market Investment Trends & Emerging - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year - Yahoo Finance
Leerink Partnrs Weighs in on Editas Medicine Q1 Earnings - MarketBeat
New Horizons in Biomedical CRISPR Gene Editing Market Exploring - openPR.com
Leber Congenital Amaurosis Market to Show Remarkable Growth - openPR.com
Raymond James Financial Inc. Takes $303,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Genome Editing Market Growth 2025: Trends, Consumer Demand, - openPR.com
SEC Form PRE 14A filed by Editas Medicine Inc. - Quantisnow
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? - Yahoo Finance
Editas Medicine: Do The Risks Outweigh The Rewards? (NASDAQ:EDIT) - Seeking Alpha
Top 5 CRISPR Companies To Invest In (April 2025) - Securities.io
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline - Investing.com
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline By Investing.com - Investing.com South Africa
RNA Pioneer and Former Editas CEO Joins Codexis Board: Strategic Move for RNA Therapeutics Push - Stock Titan
Zacks Research Forecasts Editas Medicine FY2027 Earnings - MarketBeat
Gene Editing Market Detailed In New Research Report 2025-2032 | - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 35% But Perhaps Not Attractive Enough - simplywall.st
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):